TABLE 2.
Baseline patient demographic characteristics by treatment1
| Placebo | Selenate (200 μg Se) | Selenate (400 μg Se) | Selenomethionine (200 μg Se) | P | |
| n | 22 | 21 | 18 | 21 | — |
| Age | 50.8 ± 11.12,x | 59.5 ± 6.7y | 54.9 ± 7.9x,y | 56.2 ± 10.0x,y | 0.011 |
| Sex, M, % | 64 | 57 | 61 | 62 | 0.9773 |
| BMI, kg/m2 | 29.7 ± 6.1 | 29.9 ± 3.8 | 30.2 ± 6.3 | 31.2 ± 6.8 | 0.935 |
| Race, n | 0.1674 | ||||
| Caucasian | 22 | 21 | 14 | 21 | |
| Black | 0 | 0 | 1 | 0 | |
| Hispanic | 0 | 0 | 2 | 0 | |
| Asian | 0 | 0 | 1 | 0 | |
| Taking vitamin supplements containing selenium, n | 2 | 2 | 1 | 1 | 0.9113 |
1
Values that do not share a common superscript letter are significantly different at P < 0.05 on the basis of the Kruskal-Wallis H test.
2
Mean ± 1 SD (all such values).
3
On the basis of Pearson’s chi-square test.
4
On the basis of the likelihood ratio test.